nonacog alfa: clinical use

Prescribing considerations

• Initiate and supervise treatment through an experienced haemophilia service.
• Individual response and recovery vary; assess clinical effectiveness when changing factor IX products.
• Initial administrations may require medical observation because severe hypersensitivity can occur.
• Record the product name and batch number for every administration.
• Continuous infusion is not approved or recommended.

Contraindications and cautions

• Hypersensitivity to nonacog alfa or any excipient.
• Known allergy to hamster proteins.
• Use caution where thrombosis or disseminated intravascular coagulation is a concern, and in people with cardiovascular or hepatic risk factors, recent surgery or indwelling venous catheters.
• Evidence in previously untreated patients is limited.

Monitoring

• Measure plasma factor IX activity when clinically indicated, particularly around major surgery or if response is inadequate.
• Interpret one-stage clotting assay results with awareness that the thromboplastin reagent and reference standard can materially affect results.
• Test for factor IX inhibitors when clinical response is insufficient or hypersensitivity occurs.
• Monitor for hypersensitivity and thrombotic complications.

Clinical pharmacology

Nonacog alfa is a recombinant, vitamin K-dependent coagulation factor IX protein produced in genetically engineered Chinese hamster ovary cells. Activated factor IX works with activated factor VIII to activate factor X, promoting thrombin and fibrin formation. Children may have higher clearance, shorter half-life and lower recovery than adults.

Formulation and product differences

• The selected products are powder-and-solvent presentations of the same recombinant factor IX formulation and differ in vial strength and resulting concentration after reconstitution.
• Each selected pack supplies sodium chloride solvent, a vial adapter and infusion equipment.
• The powder contains sucrose, glycine, L-histidine and polysorbate 80; the prepared product is essentially sodium-free per vial, although multiple vials increase total sodium exposure.

Injection

Route: Parenteral

Strengths: 250 units, 500 units, 1000 units, 2000 units, 3000 units